Veliparib, a PARP-1/2 inhibitor, was tested with gemcitabine and radiotherapy in locally advanced pancreatic cancer in a phase 1 study, and the results supported a phase 2 validation study [54]. The gene discussed is PARP1; the disease is familial pancreatic carcinoma.